The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock

Medtronic plc MDT has begun the broad U.S. commercial rollout of the MiniMed 780G system integrated with Abbott’s ABT Instinct sensor, designed exclusively for MiniMed systems. Earlier this year, the FDA cleared the SmartGuard algorithm as an interoperable automated glycemic controller (iAGC), enabling integration with the Instinct sensor for type 1 diabetes.The latest development marks a major achievement in diabetes technology and delivers a smart, seamless way to manage diabetes.MDT Stock’s Likely Trend Following the NewsFollowing the announcement yesterday, MDT shares dropped 1.3%, closing at $102.03. On a promising note, Medtronic’s Diabetes business is in a strong innovation cycle. In the last few months, the MiniMed 780G system received CE Mark for three expanded indications, including for type 2, for children as young as age two and during pregnancy. It also secured U.S. FDA approval for use in adults aged 18 and above, with insulin-requiring type 2 diabetes. Pairing MiniMed 780G with the Instinct sensor further advances the company’s efforts to bring the proven clinical outcomes of the system to more people living with diabetes. Accordingly, the news should help support a rebound in MDT stock performance. Medtronic has a market capitalization of $132.48 billion at present. Going by the Zacks Consensus Estimate, the company’s fiscal 2026 earnings per share (EPS) are expected to grow 2.9% over 2025. It has delivered an earnings beat of 2.75%, on average, in the trailing four quarters.More on MDT’s Newest DevelopmentMiniMed 780G is Medtronic's most advanced automated insulin delivery system that automatically adjusts insulin every five minutes based on real-time glucose readings, helping reduce highs and lows, and making diabetes management easier and less time-consuming. Abbott's Instinct sensor is based on its most advanced continuous glucose monitoring (CGM) technology, featuring the world's smallest, thinnest, most discreet sensor. It offers a wear time of up to 15 days.Image Source: Zacks Investment ResearchWhen paired with the MiniMed 780G system, the Instinct sensor provides real-time glucose readings, which the system uses to automate insulin adjustments every five minutes, helping people with diabetes spend less time managing their condition and more time living their lives.Additionally, the launch of the Instinct sensor expands Medtronic's sensor portfolio, offering more choice alongside the recently launched Simplera Sync sensor and the Guardian 4 sensor. All are part of a growing ecosystem designed to make diabetes care easier and more personalized.Industry Prospects Favoring MDTAccording to Grand View Research, the global diabetes devices market wasvalued at$30.31 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 7.5% through 2030. Key factors fueling the market’s growth are the growing prevalence of diabetes, advanced technology, increasing usage of insulin delivery devices and the rise in obesity rates.More Updates From MDTMedtronic released its fiscal 2026 second-quarter earnings last month, with worldwide revenues of $8.961 billion representing a 6.6% year-over-year increase. The Diabetes business saw particular strength in international markets, which grew 11%. Within the Cardiac Ablation Solutions business, the company gained share as the Pulsed Field Ablation franchise grew more than 300% in the United States as well as in international markets, based on the strength of the Affera mapping system and the Sphere-9 dual energy and high-density mapping catheter.MDT Stock Price PerformanceYear to date, shares of MDT have gained 27.8% compared with the industry’s 3.9% growth.MDT’s Zacks Rank and Other Top PicksMedtronic currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the broader medical space are Globus Medical GMED and Boston Scientific BSX. While Globus Medical sports a Zacks Rank #1 (Strong Buy), Boston Scientific carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.Estimates for Globus Medical’sEPS have increased 11.8% in the past 30 days. Shares of the company have risen 5.5% in the past year against the industry’s 0.6% fall. GMED’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.2%. In the last reported quarter, it delivered an earnings surprise of 49.4%. Boston Scientific shares have jumped 9% in the past year. Estimates for the company’s 2025 EPS have increased by 1 cent to $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Globus Medical, Inc. (GMED): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks